IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients
No clinically significant adverse events observed
Actively enrolling Phase 2a '201' clinical trial of IkT-148009 in patients with untreated Parkinson's disease